Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Corona, V. Boddi, G. Balercia, G. Rastrelli, G. Vita, A. Sforza, G. Forti, E. Mannucci, M. Maggi (2010)
The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction.The journal of sexual medicine, 7 4 Pt 1
Xi Zheng, X. Cui, Zhi Gao, Yang Zhao, Y. Lin, W. Shih, Mou-tuan Huang, Yue Liu, A. Rabson, Bandaru Reddy, Chung Yang, A. Conney (2010)
Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen IndependenceCancer Prevention Research, 3
C. Huggins, R. Stevens, C. Hodges (1941)
STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLANDArchives of Surgery, 43
C. Schooling, Shiu Lun, Au Yeung, G. Freeman, B. Cowling (2013)
The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trialsBMC Medicine, 11
Steven Chang, L. Harshman, J. Presti (2010)
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 25
RW Ross, W Xie, MM Regan (2008)
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect., 112
D. Bansal, K. Undela, S. D’Cruz, F. Schifano (2012)
Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational StudiesPLoS ONE, 7
J. Wright, E. Kwon, E. Ostrander, R. Montgomery, D. Lin, R. Vessella, J. Stanford, E. Mostaghel (2011)
Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer OutcomesCancer Epidemiology, Biomarkers & Prevention, 20
R. Ross, W. Xie, M. Regan, M. Pomerantz, M. Nakabayashi, T. Daskivich, O. Sartor, M. Taplin, P. Kantoff, W. Oh (2008)
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancerCancer, 112
C. Park, I. Lee, W. Kang (2001)
Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death.Carcinogenesis, 22 10
H. Pressler, T. Sissung, D. Venzon, D. Price, W. Figg (2011)
Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of ProgressionPLoS ONE, 6
D. Boudreau, Onchee Yu, D. Buist, D. Miglioretti (2008)
Statin use and prostate cancer risk in a large population-based settingCancer Causes & Control, 19
Xinjian Peng, Wenping Li, Liang Yuan, R. Mehta, L. Kopelovich, D. Mccormick (2013)
Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21PLoS ONE, 8
S. Bonovas, K. Filioussi, N. Sitaras (2008)
Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studiesInternational Journal of Cancer, 123
W. Oh, J. Hayes, Carolyn Evan, J. Manola, D. George, Helen Waldron, M. Donovan, J. Varner, John Orechia, Beth Katcher, Diana Lu, ArthurE. Nevins, R. Wright, Lauren Tormey, J. Talcott, M. Rubin, M. Loda, W. Sellers, J. Richie, P. Kantoff, J. Weeks (2006)
Development of an integrated prostate cancer research information system.Clinical genitourinary cancer, 5 1
L. Mucci, M. Stampfer (2014)
Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 1
E. Platz, M. Leitzmann, K. Visvanathan, E. Rimm, M. Stampfer, W. Willett, E. Giovannucci (2006)
Statin drugs and risk of advanced prostate cancer.Journal of the National Cancer Institute, 98 24
E. Scosyrev, Scott Tobis, Heather Donsky, Guan Wu, J. Joseph, Hani Rashid, E. Messing (2013)
Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta‐analysis of eight cohort studiesBJU International, 111
N. Fujimoto, Tatsuhiko Kubo, H. Inatomi, H. Bui, M. Shiota, T. Sho, T. Matsumoto (2013)
Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivationProstate Cancer and Prostatic Disease, 16
Jianghong Wu, W. Wong, F. Khosravi, M. Minden, L. Penn (2004)
Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced ApoptosisCancer Research, 64
Yueh-Ching Chou, Yi-Kai Wang, M. Charng, Y. Ueng (2013)
Corrigendum to “Determination of serum atorvastatin concentrations in lipid-controlling patients with and without myalgia syndrome” [J Food Drug Anal 21 (2013) 147–153]Journal of Food and Drug Analysis, 21
T. Murtola, P. Pennanen, H. Syvälä, M. Bläuer, T. Ylikomi, T. Tammela (2009)
Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial Cells at therapeutic concentrationsThe Prostate, 69
Ming Yang, W. Xie, E. Mostaghel, M. Nakabayashi, L. Werner, T. Sun, M. Pomerantz, M. Freedman, R. Ross, M. Regan, N. Sharifi, W. Figg, S. Balk, Myles Brown, M. Taplin, W. Oh, G. Lee, P. Kantoff (2011)
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
M. Weis, C. Heeschen, A. Glassford, J. Cooke (2002)
Statins Have Biphasic Effects on AngiogenesisCirculation: Journal of the American Heart Association, 105
S. Freedland, S. Freedland, Robert Hamilton, L. Gerber, L. Gerber, L. Bañez, D. Moreira, D. Moreira, G. Andriole, R. Rittmaster (2013)
Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE studyProstate Cancer and Prostatic Diseases, 16
D. Boudreau, Onchee Yu, Jeanene Johnson (2010)
Statin use and cancer risk: a comprehensive reviewExpert Opinion on Drug Safety, 9
S. Nielsen, B. Nordestgaard, S. Bojesen (2012)
Statin use and reduced cancer-related mortality.The New England journal of medicine, 367 19
J. Goldstein, Michael Brown (1990)
Regulation of the mevalonate pathwayNature, 343
RJ Hamilton, LL Banez, WJ Aronson (2010)
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database., 116
Henry Park, Henry Park, Henry Park, J. Schoenfeld, R. Mailhot, R. Mailhot, M. Shive, M. Shive, R. Hartman, R. Hartman, R. Ogembo, R. Ogembo, L. Mucci (2013)
Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology, 24 6
R. Hamilton, L. Bañez, W. Aronson, M. Terris, E. Platz, C. Kane, J. Presti, C. Amling, S. Freedland (2010)
Statin medication use and the risk of biochemical recurrence after radical prostatectomyCancer, 116
E. Platz, C. Tangen, P. Goodman, C. Till, H. Parnes, W. Figg, D. Albanes, M. Neuhouser, E. Klein, M. Lucia, I. Thompson, A. Kristal (2014)
Statin drug use is not associated with prostate cancer risk in men who are regularly screened.The Journal of urology, 192 2
Y. Chou, Yi-Kai Wang, M. Charng, Y. Ueng (2013)
Determination of serum atorvastatin concentrations in lipid- controlling patients with and without myalgia syndromeJournal of Food and Drug Analysis, 21
ImportanceStatin use has been associated with improved prostate cancer outcomes. Dehydroepiandrosterone sulfate (DHEAS) is a precursor of testosterone and a substrate for SLCO2B1, an organic anionic transporter. We previously demonstrated that genetic variants of SLCO2B1 correlated with time to progression (TTP) during receipt of androgen deprivation therapy (ADT). Statins also use SLCO2B1 to enter cells, and thus we hypothesized that they may compete with DHEAS uptake by the tumor cells. ObjectiveTo evaluate whether statin use prolongs TTP during ADT for hormone-sensitive prostate cancer. Design, Setting, and ParticipantsIn vitro studies were performed using prostate cancer cell lines at an academic, comprehensive cancer center. Statin use was retrospectively analyzed in 926 patients who had received ADT for biochemical or metastatic recurrence or de novo metastatic prostate cancer between January 1996 and November 2013. Main Outcomes and MeasuresTo determine whether statins interfere with DHEAS uptake, we performed in vitro studies using prostate cancer cell lines. Next, we queried our institutional clinical database to assess for an association between statin use and TTP during ADT using multivariable Cox regression analysis and adjusted for known prognostic factors. ResultsIn vitro, we demonstrated that statins block DHEAS uptake by competitively binding to SLCO2B1. In our ADT cohort of 926 patients, 283 (31%) were taking a statin at ADT initiation. After a median follow-up of 5.8 years, 644 patients (70%) had experienced disease progression while receiving ADT. Median TTP during ADT was 20.3 months (95% CI, 18-24 months). Men taking statins had a longer median TTP during ADT compared with nonusers (27.5 [95% CI, 21.1-37.7] vs 17.4 [95% CI, 14.9-21.1] months; P < .001). The association remained statistically significant after adjusting for predefined prognostic factors (adjusted hazard ratio, 0.83 [95% CI, 0.69-0.99]; P = .04). The positive statin effect was observed for both patients with and without metastases (adjusted hazard ratio, 0.79 [95% CI, 0.58-1.07] for M0 disease and 0.84 [95% CI, 0.67-1.06] for M1 disease; P for interaction = .72). Conclusions and RelevanceStatin use at the time of ADT initiation was associated with a significantly longer TTP during ADT even after adjustment for known prognostic factors. Our in vitro finding that statins competitively reduce DHEAS uptake, thus effectively decreasing the available intratumoral androgen pool, affords a plausible mechanism to support the clinical observation of prolonged TTP in statin users.
JAMA Oncology – American Medical Association
Published: Jul 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.